Literature DB >> 3139445

The epidemiology of respiratory tract pathogens in southern Netherlands.

B I Davies1, F P Maesen.   

Abstract

Results of sputum cultures and susceptibility tests have been reviewed for the years 1977-1986, with approximately 1,700 positive cultures per year. Haemophilus influenzae always occupied the first place, being grown in 65% of positive specimens in 1977 and 37% in 1986. Streptococcus pneumoniae occupied the second place, rising from 17 to 27% in the same period, during which Branhamella catarrhalis rose from 5 to 26%. Based on the frequency of occurrence of individual bacterial species in the sputum cultures and on the percentage of strains resistant to ampicillin, cotrimoxazole, doxycycline, erythromycin and ofloxacin, theoretical chances of failure of blind therapy were calculated and found to be most advantageous for ofloxacin and cotrimoxazole. No explanation could be given for the increase in beta-lactamase production by B. catarrhalis, but the disappearance of Haemophilus parainfluenzae may have been due to improvements in the identification procedure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139445

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Genetic basis of tetracycline resistance in Moraxella (Branhamella) catarrhalis.

Authors:  M C Roberts; B A Brown; V A Steingrube; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 2.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Expression of the CopB outer membrane protein by Moraxella catarrhalis is regulated by iron and affects iron acquisition from transferrin and lactoferrin.

Authors:  C Aebi; B Stone; M Beucher; L D Cope; I Maciver; S E Thomas; G H McCracken; P F Sparling; E J Hansen
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

4.  Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis.

Authors:  C Aebi; L D Cope; J L Latimer; S E Thomas; C A Slaughter; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope.

Authors:  J C McMichael; M J Fiske; R A Fredenburg; D N Chakravarti; K R VanDerMeid; V Barniak; J Caplan; E Bortell; S Baker; R Arumugham; D Chen
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.

Authors:  B A Brown; R J Wallace; C W Flanagan; R W Wilson; J I Luman; S D Redditt
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

7.  A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model.

Authors:  M E Helminen; I Maciver; J L Latimer; L D Cope; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 8.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay.

Authors:  M E Helminen; R Beach; I Maciver; G Jarosik; E J Hansen; M Leinonen
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

10.  Tetracycline resistance in Moraxella (Branhamella) catarrhalis: demonstration of two clonal outbreaks by using pulsed-field gel electrophoresis.

Authors:  M C Roberts; Y J Pang; R C Spencer; T G Winstanley; B A Brown; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.